中重度衰弱老年人的实用处方最佳实践
多药共用常见于老年人,中重度衰弱者常被药物临床试验排除,预后获益可能因预期寿命缩短而减少,且因衰弱易感性、药物相互作用及治疗负担而用药伤害风险增高。本文结合近期指南,提出平衡药物风险与获益的实用处方方法,以减少用药相关伤害。
要点
- 中重度衰弱老年人常被药物临床试验排除,缺乏确定性证据。
- 该人群用药预后获益可能因预期寿命缩短而减少,伤害风险增高。
- 实用方法需结合个体情况与目标,平衡药物风险与获益。
核心结论
- 中重度衰弱老年人需采用实用处方方法,结合个体情况与目标平衡药物风险与获益,以减少用药相关伤害。
研究设计与样本
- 本文为最佳实践文章,基于近期指南论述中重度衰弱老年人实用处方的需求与方法。
主要发现
- 中重度衰弱老年人常被药物临床试验排除,缺乏确定性临床 trial 数据。
- 该人群用药预后获益可能因预期寿命缩短而减少。
- 该人群因衰弱易感性、药物相互作用、药物-疾病相互作用及治疗负担而用药伤害风险增高。
- 用药相关伤害是现代医疗中导致健康受损(包括诱发住院)的主要因素之一。
临床怎么用
- 对中重度衰弱老年人,应结合个体情况与目标,实用地平衡药物风险与获益。
- 可参考近期指南以减少中重度衰弱老年人的用药相关伤害。
局限性
- 缺乏针对中重度衰弱老年人的确定性临床试验数据,优化照护具有挑战性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polypharmacy is common among older people. Optimal prescribing balances medicine-related benefits and potential harms. People with moderate to severe frailty, as defined by the Clinical Frailty Scale, are infrequently included in drug clinical trials. For this group, prognostic benefits of medicines are likely to be diminished by reduced life expectancy. They are also at increased risk of harm from medicines due to a combination of problems, including the characteristic vulnerability of people with frailty, drug-drug interactions, drug-disease interactions and therapeutic burden. In modern healthcare, medicine-related harm is a major contributor to reduced well-being, including provocation of hospital admissions. In the absence of definitive clinical trial data for this population, optimising care is challenging. A pragmatic approach balances risks and benefits of prescribing for a person with frailty alongside the individual's circumstances and goals. A recently developed guideline aims to help reduce medicine-related harm for people with moderate to severe frailty. In this best practice article, we will make a case for the need for change and outline a pragmatic approach to balance medication risks and benefits, with reference to the recent guidance.
引用
- Woodford H, Avery T, Pollock L, et al. Best practice in pragmatic prescribing for older people with moderate to severe frailty. Age Ageing. 2026. PMID: 42200477. doi:10.1093/ageing/afag154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。